AVR
Anteris Technologies Global Corp.
NASDAQ · Healthcare · Medical - Devices · AU
$6.18
+2.15%Sep 23, 2026, 11:30 UTC
Anteris Aus Operations Pty Ltd amended its Supply & Quality Agreement with Harvey Industries Group Pty Ltd, extending the term until the earlier of December 31, 2026 or the effective date of a replacement agreement.
Sep 17, 2026, 21:08 UTC
Anteris Technologies Global Corp. granted equity awards to Vice Chairman and CEO Wayne Paterson, David St Denis, and Matthew McDonnell effective September 12, 2026.
Aug 12, 2026, 00:00 UTC
Anteris Technologies Global Corp. reported its Q2 2026 financial results, with H1 2026 revenues of $1.503 million, up 28% year-over-year, and a net loss after tax of $51.675 million for H1 2026.
Aug 11, 2026, 08:09 UTC
L1 Capital Pty Ltd, a major shareholder of Anteris Technologies Global Corp., sold 174,721 shares of the company's stock on August 6, 2026, at an average price of $8.10, totaling $1,415,240.10.
Source:Jun 8, 2026, 10:00 UTC
Anteris Technologies Global Corp. received full regulatory clearance from the French National Agency for Medicines and Health Products Safety (ANSM) for its DurAVR Transcatheter Heart Valve global pivotal trial (PARADIGM Trial).